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Abstract
Background: Glioblastoma (GB) is the most malignant brain tumor in adults. It is characterized by angiogenesis
and a high proliferative and invasive capacity. Standard therapy (surgery, radiotherapy and chemotherapy with
temozolomide) is of limited efficacy. Innovative anticancer drugs targeting both tumor cells and angiogenesis are
urgently required, together with effective systems for their delivery to the brain. We assessed the ability of human
mesenchymal stromal cells (MSCs) to uptake the multikinase inhibitor, sorafenib (SFN), and to carry this drug to a
brain tumor following intranasal administration.
Method: MSCs were primed with SFN and drug content and release were quantified by analytical chemistry techniques.
The ability of SFN-primed MSCs to inhibit the survival of the human U87MG GB cell line and endothelial cells was
assessed in in vitro assays. These cells were then administered intranasally to nude mice bearing intracerebral U87MG
xenografts. Their effect on tumor growth and angiogenesis was evaluated by magnetic resonance imaging and
immunofluorescence analyses, and was compared with the intranasal administration of unprimed MSCs or SFN alone.
Results: MSCs took up about 9 pg SFN per cell, with no effect on viability, and were able to release 60% of the primed
drug. The cytostatic activity of the released SFN was entirely conserved, resulting in a significant inhibition of U87MG
and endothelial cell survival in vitro. Two intranasal administrations of SFN-primed MSCs in U87MG-bearing mice resulted
in lower levels of tumor angiogenesis than the injection of unprimed MSCs or SFN alone, but had no effect on tumor
volume. We also observed an increase in the proportion of small intratumoral vessels in animals treated with unprimed
MSCs; this effect being abolished if the MSCs were primed with SFN.
Conclusion: We show the potential of MSCs to carry SFN to brain tumors following an intranasal administration. However,
the therapeutic effect is modest probably due to the pro-tumorigenic properties of MSCs, which may limit the action of
the released SFN. This calls into question the suitability of MSCs for use in GB therapy and renders it necessary to
find methods guaranteeing the safety of this cellular vector after drug delivery.
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Background
Glioblastoma (GB) is the most common, invasive and
aggressive primary brain tumor in humans. Over the last
12 years or so, most patients with GB have been treated
with the Stupp protocol [1], consisting of surgical resec-
tion followed by radiotherapy with concomitant and
adjuvant temozolomide (TMZ) chemotherapy. The effi-
cacy of this treatment is limited, with median overall
survival of no more than 15 months [2]. GB treatment is
complicated by the high resistance of these tumors to
standard chemotherapy agents, the critical role of angio-
genesis in their growth and spread and the blood-brain
barrier (BBB), which serves as a physiological obstacle to
the delivery of drugs to the central nervous system. The
development of innovative anticancer drugs targeting
both tumor cells and blood vessels is therefore urgently
required, together with effective systems for delivering
these drugs to the brain.
In recent years, targeted molecular therapies based on
the use of inhibitors of several pathways involved in the
oncogenic process in GB have emerged [3–5]. Sorafenib
(SFN) (Nexavar) is one such inhibitor. It is an oral multiki-
nase inhibitor that targets both cell surface kinase receptors
(VEGFR and PDGFR) and downstream intracellular serine/
threonine kinases [6] resulting in diverse cellular effects,
such as induction of tumor cell apoptosis and autophagy,
and reduction of angiogenesis [7–9]. SFN showed efficacy
against different solid tumors and is already approved for
the treatment of advanced hepatocellular carcinoma, renal
cell carcinoma, and thyroid cancer [6]. In clinical studies in
patients with progressive or recurrent GB, oral administra-
tion of SFN has been shown to be of very limited efficacy
as a monotherapy or in combination with TMZ or other
targeted drugs, such as erlotinib [10–16]. This lack of
efficacy is not restricted to SFN; other drugs fell short
of expectations because they penetrated the brain only
inefficiently via the BBB or were unable to target tumor
cells. Various approaches have been developed to overcome
these limitations, including the use of mesenchymal stromal
cells (MSCs), which can cross the BBB and display brain
tumor tropism after systemic and local administration
[17–21]. This property has generated considerable
interest in the use of MSCs as treatment vectors for
GB [22–25].
MSCs have been genetically modified to overexpress sev-
eral antitumor factors, such as interleukins, interferons,
pro-drugs, oncolytic viruses, anti-angiogenic agents, pro-
apoptotic proteins, and growth factor antagonists [26, 27].
Despite promising results in animal models, the genetic
manipulation of MSCs for clinical application is not risk-
free [28]. We and others have shown that MSCs can deliver
chemotherapy drugs to brain tumors without genetic modi-
fication [29–33]. For example, we have shown that MSCs
can deliver lipid nanocapsules containing an organometallic
complex (ferrociphenol) in the heterotopic and orthotopic
U87MG GB models [29, 31]. MSCs were also able to take
up and release paclitaxel and to induce cytotoxic damage in
GB xenografts [32, 34]. A major concern to use these thera-
peutic cells is the delivery method. The surgical injection of
MSCs directly into the brain is the most frequently used
method of delivery. However, this method is invasive
making a repeated treatment option difficult. In a clin-
ical context, systemic administration of this therapeutic
tool would be simpler, less costly and would allow for a
chronic treatment. Intravascular applications of MSCs
could be an option but major obstacles are the entrap-
ment and elimination of cells in peripheral organs and
the risk of vascular and pulmonary embolization [35, 36].
Intranasal administration of MSCs appears to be a prom-
ising noninvasive and safe alternative delivery method to
surgical injection or to intravascular administration [37].
Intranasally administered MSCs were able to enter the
brain in experimental glioma models [19] as well as in
mouse models of Alzheimer’s and Parkinson’s disease [38]
and neonate ischemic brain damage models [39].
In this study, we evaluated the ability of MSCs to take
up SFN and target it to the tumor in the orthotopic
U87MG GB model, following intranasal administration.
We paid particular interest to the effects of SFN-primed
MSCs on tumor growth and angiogenesis, through com-
parisons with the intranasal administration of unprimed
MSCs or SFN alone.
Methods
Cell culture and reagents
MSCs were obtained from iliac crest aspirates from a
human male post-mortem organ donor (protocol agreed
by the French Agency of Biomedicine), and were isolated
as previously described [17, 40]. This cell population was
expanded by culture in StemMACS™ MSC Expansion
Media Kit XF (Miltenyi Biotec, Paris, France) in a humidi-
fied incubator at 37 °C, under an atmosphere containing
5% CO2, until 70% confluence. All experiments were per-
formed with cells between passages 4 and 5.
The human U87MG GB cell line was obtained from the
ATCC (LGC Promochem, Molsheim, France). Cells were
maintained in Dulbecco’s modified eagle medium-high
glucose medium (DMEM-HG, Lonza, Verviers, Belgium)
containing 10% fetal bovine serum (FBS) (Fisher Scientific,
Illkirch, France) and 1% antibiotics (Sigma-Aldrich, St.
Quentin Fallavier, France), under an atmosphere contain-
ing 5% CO2 (37 °C), in a humidified incubator, until they
reached 80% confluence.
Human umbilical vein endothelial cells (HUVECs)
were purchased from Lonza. Cells were cultured accord-
ing to the supplier’s instructions, in endothelial cell
growth medium-2 (EGM-2) in a humidified chamber at
37 °C, under an atmosphere containing 5% CO2.
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SFN was purchased from LC Laboratories (Woburn,
USA). The stock solution was prepared in DMSO (Sigma-
Aldrich), at a concentration of 100 mM. Aliquots were
stored at −20 °C.
Sensitivity of HUVECs, U87MG and MSCs to SFN
HUVECs and U87MG cells were plated in 96-well plates
at densities of 5 × 103 cells/cm2 and MSCs were plated
at a density of 1 × 104 cells/cm2. After 48 h, the culture
medium was removed and cells were treated with SFN
at concentrations of 0.001 to 100 μM. Four days later,
the medium was removed from the wells and the plates
were stored at −80 °C until their use for assays. Cell sur-
vival was estimated with the CyQUANT® cell proliferation
assay kit, according to the manufacturer’s instructions
(Fisher Scientific).
Priming of MSCs with SFN
MSCs (4 × 105 cells) were incubated for 1 h at 37 °C
with 1 mL SFN (20 or 100 μM) in Hank’s balanced salt
solution (HBSS), with Ca2+ and Mg2+ (Lonza). At the end
of the incubation period, cells were washed twice with
HBSS, counted, and used for in vitro and in vivo experi-
ments, as described below.
In vitro characterization of SFN-primed MSCs
SFN content of SFN-primed MSCs
The SFN content of MSCs was measured by high per-
formance liquid chromatography (HPLC) method. SFN-
primed MSCs (4 × 105 cells) were suspended in 50 μL
H2O. We then successively added 50 μL tetrahydrofuran
and 200 μL methanol. A filtration was performed using a
Millex-LG 0.2 μm filter (Millipore, Guyancourt, France)
and 10 μL was injected onto the HPLC system. Chromatog-
raphy was performed with the Waters modular system
(600/717/996/2414) (Waters, Saint-Quentin-en-Yvelynes,
France) on a SunFire® C18 column (150 × 4.6 mm; 5 μm)
at 37 °C. SFN was eluted with an isocratic mobile phase
(acetonitrile/methanol/1% acetic acid, at a ratio of 35:38:27)
at a flow rate of 1 mL/min, with monitoring at 266 nm.
The chromatograms were recorded and integrated with
Empower 3 software (Waters). The range of linear response
was 0.5–32 μg/mL.
Viability of SFN-primed MSCs
SFN-primed MSCs were used to seed 96-well plates, and cell
survival was estimated one and seven days later, with the
CyQUANT® cell proliferation assay kit, as described above.
Release of SFN from SFN-primed MSCs
SFN-primed MSCs (3 × 105) were used to seed Transwell®
inserts with a pore size of 0.4 μm (Millipore) in DMEM-HG
supplemented with 10% FBS and 1% antibiotics. We moni-
tored SFN release at different time points, by collecting the
cell-conditioned medium (CM) from the lower compart-
ment at 4, 24, 48, 72 and 96 h. Quantification of SFN in the
CM was determined by liquid chromatography tandem-
mass spectrometry (LC-MS/MS).
Chromatography was performed with the Waters Alli-
ance® 2695 system, with an Uptisphere® 5 ODB C18
column (150 × 2.0 mm) (Interchim, Montluçon, France).
The mobile phase consisted of an isocratic mixture of 0.1%
formic acid in water/0.1% formic acid in acetonitrile: 20/80
(v/v). The column temperature was set at 25 °C and the
flow rate was 0.3 mL/min, with a total run time of
10 min. The total HPLC effluent was analyzed in a
Quattro® Micro triple quadrupole mass spectrometer
(Waters). Ionization was achieved by the electrospray
method, in positive-ion mode. The mass spectrometer was
operated in multiple reaction monitoring (MRM) mode.
The (M – H) + m/z transition for SFN was 465 → 270. A
typical retention time for SFN was 2.3 min. Quantification
was achieved with QuantLynx® (Waters), by comparing the
observed peak area ratios of SFN samples with a calibration
curve obtained under the same experimental conditions.
The range of the linear response was large, extending from
50 to 1000 ng/mL.
Toxicity of SFN-primed MSCs to U87MG cells and HUVECs
We assessed the in vitro toxicity of SFN-primed MSCs to
U87MG cells and HUVECs, by performing coculture ex-
periments in Transwell® plates, with inserts with a pore
size of 0.4 μm (Millipore). HUVECs and U87MG cells
(6 × 103 cells/well) were placed in the lower compartment.
After 48 h, we added SFN, or unprimed or SFN-primed
MSCs to the upper compartment. Three days later, the in-
serts were removed and a CyQUANT® cell proliferation
assay was performed.
In vivo effect of SFN-primed MSCs
U87MG GB model
Female Swiss nude mice (8–10 weeks old) were obtained
from Charles River Laboratories (L’Arbresle, France).
The protocol was approved by the Committee on the
Ethics of Animal Experiments of the “Pays de la Loire”
(Permit no. 01785.01). Animals were anesthetized by an
intraperitoneal injection of xylazine (13 mg/kg body
weight) and ketamine (100 mg/kg body weight) and were
positioned in a Kopf stereotaxic instrument. On day 0
(D0), U87MG cells (3 × 104) in 5 μL HBSS with Ca2+
and Mg2+ were injected into the striatum of mice [coor-
dinates: 2.1 mm lateral to the bregma, 0.5 mm anterior
and 3 mm interior to the outer border of the cranium].
Analysis of the distribution of MSCs in the U87MG tumor
after their intranasal administration
Intranasal delivery was performed as previously described
[19], but with minor modifications. Thirty minutes before
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cell administration, anesthetized U87MG tumor-bearing
mice (D12) were placed in a supine position and the
nasal cavity of each animal was treated with total of
100 U hyaluronidase (Sigma-Aldrich) in the form of
four repeated inoculations at two-minute intervals
(3 μL per nostril). We then applied either HBSS with
Ca2+ and Mg2+, or 6 × 105 MSCs in the same conditions.
For analysis of the distribution of MSCs in the U87MG
tumor, the animals were killed three or seven days later
(D15 and D19, respectively). Brains were snap-frozen in iso-
pentane cooled with liquid nitrogen and stored at −80 °C.
Coronal sections of the brain were cut at 10 μm intervals
and collected on silane-treated slides. MSCs in tumor cryo-
sections were detected by fluorescence in situ hybridization
(FISH), with a human Y-chromosome probe, as previously
described [34]. The DNA probe was complementary to the
highly repetitive human satellite III sequences located close
to the centromeric region of the human Y-chromosome
DYZ1 locus (CEPY) and was labeled with the SpectrumOr-
ange fluorochrome (Vysis, Abbott Molecular, Rungis,
France).
Cryosections of four mice killed at day 15 or day 19 were
analyzed under a fluorescence microscope (Axioscope® 2
light microscope, Zeiss, Le Pecq, Germany). Y+ MSCs were
counted on nine cryosections per mouse corresponding to
the central and peripheral portions of the tumor, with the
MetaView computerized image-analysis system (Roper
Scientific, Evry, France). About five fields per cryosection,
at a magnification of ×200, were randomly selected for
each tumor.
Analysis of the effect of SFN-primed MSCs in the orthotopic
U87MG GB model
U87MG tumor-bearing mice (D6) were assigned to four
groups receiving intranasal injections according to the
protocol described above: (a) HBSS with Ca2+ and Mg2+;
(b) SFN; (c) unprimed MSCs; (d) SFN-primed MSCs.
These injections were repeated on day 10. Seven days
later, we measured tumor volume by magnetic resonance
imaging (MRI), as previously described [31], and the mice
were killed for the analysis of Ki67+ cells or CD31+ vessels
in the U87MG tumor. The presence of intratumoral Y+
MSCs in all U87MG tumor-bearing mice treated with
unprimed or SFN-primed MSCs was checked by FISH. For
CD31 and Ki67 expression analysis, brain cryosections were
allowed to dry in air, rehydrated in PBS and fixed by incu-
bation for 10 min in 4% PFA pH 7.4 at 4 °C. Nonspecific
binding was blocked by incubating the sections in 4% BSA
and 10% normal goat serum in PBS. The sections were
incubated overnight, at 4 °C, with isotype controls and
primary antibodies against endothelial cells (mouse CD31,
BD Biosciences, Le Pont de Claix, France ) and prolifera-
tive cells (Ki67, Agilent Technologies, Les Ulis, France).
The primary antibodies were detected with biotinylated
secondary antibodies and the signal was amplified with
streptavidin-FITC (Interchim). Nuclei were counterstained
with DAPI (Sigma). Cryosections of four mice from each
of the groups described above (a, b, c and d) were ana-
lyzed under an Axioscope® 2 fluorescence microscope.
CD31+ and Ki67+ cells were counted with the MetaView
computerized image-analysis system in six brain cryosec-
tions per mouse corresponding to the central and periph-
eral portions of the tumor. Five fields per cryosection, at
×200 magnification, were randomly selected for each
tumor.
Statistical analysis
Results are expressed as means ± SEM. The Kruskal–
Wallis test was used for statistical analyses. Differences
were considered significant if the p-value was < 0.05.
Results
Effect of SFN on the survival of U87MG cells, HUVECs and
MSCs
Both U87MG cells and HUVECs displayed dose-dependent
survival inhibition when treated for 4 days with SFN (Fig. 1).
SFN decreased cell viability with an IC50 of 7.39 ± 0.16 μM
for U87MG cells and 1.91 ± 0.19 μM for HUVECs. MSCs
displayed relative resistance to SFN treatment (about 40%
cell death at 100 μM).
SFN content of SFN-primed MSCs and control of their
viability
We defined the dose of SFN that MSCs could carry
without deleterious effects on their viability. For this
purpose, MSCs (4 × 105) were incubated for 1 h at 37 °C
with 20 μM (9.2 μg/mL) or 100 μM (46 μg/mL). MSCs
primed with 20 μM and 100 μM were carrying 8.8 ± 0.5
and 52.7 ± 5.0 pg SFN per cell, respectively (Fig. 2a).
The incubation of MSCs with 100 μM SFN resulted in a
40% loss of cell viability 1 day after uptake, whereas 80%
of MSCs remained viable when incubated with 20 μM
SFN (Fig. 2b). Seven days after priming, no additional
loss of viability was observed in either set of conditions
and SFN-primed MSCs retained their capacity to prolif-
erate (data not shown). Given the lower cell viability ob-
served following the incubation of MSCs with 100 μM
SFN, we decided to prime MSCs with 20 μM SFN.
Quantification and toxicity of the SFN released by SFN-
primed MSCs
We evaluated the release of SFN over time, by col-
lecting the CM from SFN-primed MSCs 4, 24, 48, 72
and 96 h after priming with SFN (20 μM) and analyz-
ing it by LC-MS/MS. We found that about 20% of
the SFN was released from SFN-primed MSCs in 4 h,
and that 60% of the drug was released in 48 h (Fig. 3a).
No further increase was observed for longer incubation
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periods. We therefore estimated that about 40% of the
SFN was retained by the cells. This result was confirmed
in a cytotoxicity assay on U87MG cells and HUVECs (Fig.
3b, c). We found that, after 3 days, 6 × 105 SFN-primed
MSCs, corresponding to the release of approximately
3.2 μg SFN, decreased U87MG cell survival by 23%,
whereas 6 × 105 unprimed MSCs had no effect on
U87MG cell viability (Fig. 3b). This decrease in survival is
intermediate between those induced by 2 μg and 6 μg of
SFN (Fig. 3b). A similar result was obtained with
HUVECs, in which 2 × 105 SFN-primed MSCs,
corresponding to the release of approximately 1.1 μg
SFN, decreased cell survival by 37%, a value close to that
induced by 1.5 μg SFN (35%) (Fig. 3c).
Analysis of the effects of the intranasal administration of
SFN-primed MSCs on U87MG growth and angiogenesis
We first controlled by FISH, the intratumoral distribution
of MSCs following intranasal administration in U87MG
tumor-bearing mice (D12, tumor volume: 2.9 ± 0.2 mm3
estimated by MRI) (n = 8) (Fig. 4a). Three days after intra-
nasal administration of MSCs, we observed MSCs in the
Fig. 2 SFN content in primed MSCs and control of their viability. a Determination of the SFN content of primed MSCs. MSCs were
incubated for 1 h at 37 °C with SFN (20 μM or 100 μM). After washing with HBSS, the SFN content of the cell pellet was determined by HPLC. b
Determination of the viability of SFN-primed MSCs. MSCs were incubated for 1 h at 37 °C with or without SFN (20 μM or 100 μM). After washing with
HBSS, cells were seeded in a 96-well plate. Cell survival was estimated after 24 h, with the CyQUANT® cell proliferation assay kit. The results obtained
for unprimed MSCs were considered to correspond to 100% survival. Data are expressed as the mean of three independent experiments ± SEM. As-
terisks (*) indicate significant differences from unprimed MSCs (p < 0.05)
Fig. 1 Effect of SFN on cell survival. U87MG cells, HUVECs and MSCs were seeded in their standard growth media and were treated with various
concentrations of SFN. Cell survival was estimated with the CyQUANT® cell proliferation assay kit. The results obtained for U87MG cells, HUVECs or
MSCs cultured with culture medium alone were considered to correspond to 100% survival. Data are expressed as the mean of four wells ±
SEM (n = 3)
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tumor mass and at the border zone between the tumor
and the normal parenchyma, consistent with tumor-
directed tropism (Fig. 4b). The tumor contained a mean
of 157 ± 27 cells/mm2 (Fig. 4c). Seven days after intranasal
administration, the number of MSCs in the tumor in-
creased to a mean of 403 ± 82 cells/mm2 (Fig. 4c). The
MSCs were evenly distributed throughout the whole
tumor (data not shown). Intranasally administered MSCs
were also able to migrate towards smaller U87MG tumors
(D6, tumor volume: 1.2 ± 0.1 mm3 estimated by MRI) and
this migration was unaffected by priming with SFN (data
not shown).
The effect of two intranasal administrations of SFN-
primed MSCs was then assessed on U87MG growth and
angiogenesis (Fig. 5a). For this purpose, U87MG tumor-
bearing mice were treated on day 6 with SFN, or with un-
primed or SFN-primed MSCs, in amounts corresponding
to an SFN dose of about 5.3 μg/mouse. This dose caused
in vitro U87MG cell and HUVEC mortality rates of close
to 40% and 70%, respectively. A control group receiving
intranasal administrations of HBSS rather than treatment
was also established. This injection protocol was repeated
on day 10. Seven days later, we assessed tumor volume,
and the numbers of intratumoral Ki67+ proliferative cells
and CD31+ vessels. Intranasal administrations of SFN, or
of unprimed or SFN-primed MSCs had no effect on
tumor volume (Fig. 5b). There was no significant differ-
ence in the number of intratumoral Ki67+ cells between
control and treated mice (Fig. 5c, d). Nevertheless, mice
receiving intranasal administrations of unprimed MSCs
had slightly higher levels of angiogenesis: they had signifi-
cantly more small vessels (< 100 μm2) than mice receiving
intranasal administrations of HBSS, SFN or SFN-primed
MSCs (Fig. 5c, e). This effect was attenuated by the prim-
ing of MSCs with SFN. Furthermore, SFN-primed MSCs
induced a significant decrease in the number of large
vessels (> 100 μm2) relative to HBSS, SFN and un-
primed MSCs (Fig. 5c, e).
Discussion
The best approach to chemotherapy for cancer is to
deliver the drug to the tumor microenvironment, to kill
tumor cells whilst maintaining the lowest possible level
of lethal damage to healthy cells, so as to limit deterior-
ation of the patient’s quality of life. Many approaches to
achieving this objective have been proposed, including
the use of MSCs, which can take up drugs and home to
tumors when administered systemically in vivo [41].
We show here that MSCs can be primed in vitro with
SFN, a targeted chemotherapy drug. We showed that a
priming concentration of 100 μM SFN caused 40%
toxicity in MSCs, whereas a priming concentration of
20 μM was only moderately cytotoxic (about 20%).
This concentration was selected to ensure that a sufficient
number of MSCs reached the brain tumor after an intra-
nasal delivery. HPLC analysis showed that MSCs primed
with 20 μM SFN contained a dose of about 9 pg SFN per
cell and were able to release 60% of the drug into the cul-
ture medium, in a time-dependent manner. This result is
consistent with the findings of Pessina et al. (2011) [34]
who estimated that about 25–30% of PTX was retained by
PTX-primed MSCs and never released. The cytostatic ac-
tivity of the released SFN was entirely conserved, resulting
in the significant inhibition of U87MG cell and HUVEC
proliferation in vitro. The mechanisms by which MSCs
excreted SFN did not seem to involve MSC death since
80% of MSCs remained viable seven days after priming
with SFN. Further work is required to determine the route
by which SFN leaves MSCs, but recent studies have
Fig. 3 SFN release from SFN-primed MSCs and in vitro toxicity of
SFN-primed MSCs to U87MG cells and HUVECs. a Profile of in vitro
SFN release by SFN-primed MSCs. b and c Viability of U87MG cells
and HUVECs following exposure to SFN or SFN-primed MSCs. Two
doses of MSCs were tested: 6 × 105 and 2 × 105 cells, corresponding to
the release of about 3.2 μg and 1.1 μg SFN, respectively. The results ob-
tained for U87MG cells and HUVECs cultured with culture medium alone
were considered to correspond to 100% survival. Data are
expressed as the mean of four wells ± SEM (n = 2) (*p < 0.05, versus
U87MG cells or HUVECs cultured with culture medium alone)
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suggested that MSCs deliver drugs by secreting membrane
microvesicles [42, 43].
We investigated the in vivo effect of SFN-primed MSCs
on the orthotopic U87MG GB model, following their intra-
nasal administration. Intranasal delivery has the advantage
over direct intracranial deliver of being noninvasive, making
repeated treatment regimens possible. Balyasnikova et al.
(2014) [19] showed, with various technical approaches
(111In-oxine, MRI and bioluminescence imaging), that
MSCs could penetrate the brain from the nasal cavity
and infiltrate intracranial glioma xenografts in a mouse
model. We validated their results with another approach,
FISH technique, which can be used for the specific
tracking of male-derived MSCs in female nude mice bear-
ing U87MG tumors, through detection of the Y-
chromosome. Three days after the intranasal administra-
tion of 6 × 105 MSCs, these cells had accumulated in the
U87MG tumor, with a mean of 157 ± 27 cells/mm2, and
even greater accumulation was observed after seven days.
These findings are similar to those of Reitz et al., (2012)
[44], who reported a mean accumulation of 54 ± 13 cells/
mm2 in U87MG tumors five days after the intranasal ad-
ministration of 3 × 105 neural stem/progenitor cells. The
accumulation of MSCs in U87MG was analyzed three
days post-MSC administration to be sure that a sufficient
number of cells could be detected by FISH but part of
Fig. 4 GB-targeted migration of MSCs after intranasal administration. a Schematic representation of the experimental model. MSCs were
administered via the nasal cavity using a pipet tip. After passing the olfactory epithelium (brown), MSCs enter the brain and migrate towards the
tumor. b Fluorescence microscopy images of tissue sections after the intranasal injection of MSCs into U87MG tumor-bearing mice. Three days (D15) and
seven days (D19) after the intranasal administration of MSCs, the MSCs had migrated and were located within the tumor mass. MSCs were detected by
red fluorescent labeling of the Y-chromosome. Nuclei were stained with DAPI. Scale bars = 100 μm. c Quantification of MSCs in the U87MG tumor three
and seven days after intranasal administration. Results are expressed as the mean number of Y+ MSCs per mm2 ± SEM (*p < 0.05, versus the number of Y+
MSCs observed at day 15)
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MSCs might have reached the tumor as early as 24 h as
observed by Balyasnikova et al. (2014) [19]. These same
authors analyzed the distribution of MSCs using 111In-
oxine-labeled MSCs and demonstrated the presence of
MSCs in the lung and stomach after intranasal delivery. It
is difficult to specify if MSCs accumulate in the brain
long-term or if they are cleared out from the brain be-
cause the survival time of tumor-bearing animals is short.
In our previous study [17], we assessed the fate of MSCs
seven days after being injected into intracranial U87MG
tumors and compared it to the fate of MSCs injected into
the striatum of healthy mice. MSCs did not seem to clear
out from the brain. We observed that 20% of MSCs
expressed Ki67 proliferation marker in the U87MG envir-
onment. In the healthy environment, we found no MSCs
in a proliferative state suggesting that factors produced by
the U87MG cells induced MSC proliferation. We ob-
served that MSCs can migrate towards large or small
U87MG tumors. This is important in a clinical context be-
cause GB is highly invasive with an infiltration that can ex-
tend several centimeters deep beyond the radiological
limits of the tumor [45]. Furthermore, as previously de-
scribed for other modified MSCs, the priming of MSCs
with SFN did not prevent their migration after intranasal
administration [18, 19].
The treatment of U87MG tumor-bearing mice with
two intranasal administrations of 6 × 105 SFN-primed
MSCs four days apart reduced tumor angiogenesis,
resulting in a significant decrease of the number of large
vessels. No decrease in angiogenesis was observed
Fig. 5 Effect of intranasal administrations of SFN, or of unprimed or SFN-primed MSCs on U87MG growth and angiogenesis. a Representation of
the treatment protocol applied to U87MG-bearing mice. b Tumor volume distribution in each group, calculated by MRI on day 17. c Immunofluores-
cence staining for Ki67 and CD31 in the tumor on day 17 (scale bar = 100 μm). d and e Quantitative results for Ki67 and CD31 immunofluorescence.
Results are expressed as the mean number of Ki67+ cells (d) or CD31+ vessels (e) per mm2 ± SEM. (ǂp < 0.05, versus HBSS, SFN and SFN-
primed MSCs; *p < 0.05, versus HBSS, SFN and unprimed MSCs)
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following the intranasal administration of SFN alone,
highlighting the potential value of MSCs as a vector for
transporting SFN to the intracerebral tumor following
administration via this route. We did not observe an ef-
fect of SFN-primed MSCs on tumor volume or the pro-
portion of Ki67+ cells in the tumor. The absence of this
effect is probably due to an insufficient dose of SFN-
primed MSCs. Siegelin et al. (2010) [8] observed that a
daily treatment of U87MG-bearing mice with SFN
(100 mg/kg) by intraperitoneal injections resulted in an in-
hibition of tumor cell proliferation and reduction of angio-
genesis with a prolonged survival of mice. We injected
only two doses of SFN-primed MSCs (about 5.3 μg/
mouse), a lower dose than was used in the study of Siege-
lin et al. corresponding to about 2 mg/mouse/day. The
dose of SFN carried by MSCs in our study corresponded
to an effective dose reducing U87MG cell survival in vitro,
but was ineffective against U87MG cells in vivo. However,
it may be sufficient to have affected endothelial cells,
which are four times more sensitive to SFN than U87MG
cells. The intranasal administration of larger numbers of
SFN-primed MSCs may be required for an effect on
U87MG growth. However, if we look at global literature
data on the use of modified MSCs to treat GB, we notice
that the effect of these cells on animal survival is relatively
modest, whatever the route of administration and the
number of administrations. For example, regarding the in-
tranasal route, Balyanikova et al. (2014) [19] showed that
the treatment of irradiated mice bearing intracranial U87-
EGFRvIII GB xenografts by four intranasal administra-
tions of 5 × 105 MSCs expressing TNF-related apoptosis
inducing ligand at one-week intervals prolonged survival
of mice of about ten days compared with irradiated mice
treated with control MSCs. Similarly, Mangraviti et al.
(2016) [18] observed that the treatment of athymic rats
bearing human brain tumor-initiating cells by two intrana-
sal inoculations of 2 × 106 human adipose-derived MSCs
(hAMSCs) producing bone morphogenetic protein 4 one
week apart induced a 21.4% increase in median survival
over that in rats treated with control hAMSCs.
The modest effect of therapeutic MSCs on GB growth
inhibition may be due to the pro-tumorigenic and pro-
angiogenic properties of these cells. Even if the role of
MSCs in cancer progression remains a matter of heated
debate, increasing numbers of studies are highlighting
these properties [41, 46–48]. In line with these studies,
we found that the intranasal administration of unprimed
MSCs induced a significant increase of the number of
small vessels in the U87MG tumor, which was abolished
when MSCs were primed with SFN. Different studies
indicate that MSCs promote angiogenesis by secreting
angiogenic factors, such as VEGF, releasing exosomes,
recruiting endothelial progenitors, and/or transdifferen-
tiating into endothelial cells [49, 50]. The mechanisms
by which SFN inhibited the angiogenic properties of
MSCs need to be elucidated. Even though we did not
observe an effect of unprimed MSCs on tumor volume
or the proportion of Ki67+ cells in the U87MG tumor,
MSCs are reported to facilitate tumor growth through
their secretion of various anti-inflammatory cytokines
and proangiogenic factors [41, 46–48]. Furthermore, MSCs
can differentiate into cancer-associated fibroblasts (CAFs),
which have been described in the stroma of carcinomas
and are known to promote tumor growth [46]. In the GB
peritumoral environment, we identified MSC-like cells that
we named GB-associated stromal cells (GASCs) which have
phenotypic and functional properties in common with
MSCs and CAFs [51–53]. Like unprimed MSCs, their
injection into intracranial U87MG tumors had no effect
on tumor volume but promoted angiogenesis with an
increase in the number of intratumoral small vessels
[52]. Other studies isolated MSC-like cells from GB
and these cells were shown to increase angiogenesis,
and GB cell proliferation and invasion [54–58]. Consistent
with these findings, it has been recently observed that the
percentage of GB-associated MSC-like cells is inversely
correlated with overall survival, indicating a role for these
cells in promoting the aggressive behavior of GB [59, 60].
All these data raise the question if MSCs are interesting
candidates as cellular vehicles for the delivery of a thera-
peutic molecule in a GB context. Even if MSCs have the
potential to deliver the therapeutic agent in the tumor,
their pro-tumorigenic and pro-angiogenic properties may
limit the effect of this agent. We need to find ways of
guaranteeing the safety of this cellular vector for clinical
use. One possibility would be to use a suicidal gene or a
small molecule to induce senescence in the MSCs after
drug delivery.
Conclusion
This study demonstrates the capacity of MSCs to carry
SFN to GB after their intranasal administration and to
decrease angiogenesis. Despite this encouraging result,
the anti-angiogenic effect was not enough to affect tumor
growth. The pro-tumorigenic and pro-angiogenic proper-
ties of MSCs may be responsible for the weakness of the
therapeutic effect observed, and the SFN released may not
be sufficient to counteract these MSC properties. These
findings call into question the suitability of MSCs for use
in the cell-based delivery of therapeutic agents for GB
treatment.
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